
JAMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP Trials
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that positive results from the two pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients [CAMP-1 and CAMP-2]) studies evaluating the safety and …
Read More